Regulating in Vitro Motility of Human Mesenchymal Stem Cells with Macrophage Migration Inhibitory Factor (MIF) and a Small-Molecule MIF Antagonist

  • Kim C. O’Connor
  • Bonnie L. Barrilleaux
  • Donald G. Phinney
  • Benjamin W. Fischer-Valuck
  • Katie C. Russell
  • Darwin J. Prockop
Conference paper
Part of the ESACT Proceedings book series (ESACT, volume 5)


Human mesenchymal stem cells (MSCs) from bone marrow possess a remarkable capacity to home to and regenerate damaged tissue, but the molecular mechanisms governing their migration and homing are not well defined. The present study reveals that a potent pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF), regulates in vitro chemokinesis of MSCs in a dose-dependent manner, inhibiting approximately 50% of migration at 100 ng/ml recombinant MIF. The small-molecule MIF antagonist (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1, 500 μg/μg rMIF) restores MSC migration to levels found in the absence of MIF. ISO-1 (85 μg/ml) increases migration to conditioned medium containing MIF from bronchial epithelial cells by ≥ 3-fold for a variety of donor MSC preparations (p < 0.05). Regulation of MIF signaling may be an effective method to control the innate homing response of MSCs and improve the efficacy of MSC therapies for injured lung and other damaged tissues.


Migration Inhibitory Factor Migration Inhibitory Factor Expression Acetic Acid Methyl Ester Stem Cell Growth Medium Recombinant Migration Inhibitory Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by a grant from the National Science Foundation (BES-0514242).


  1. Al-Abed Y, Dabideen D, Aljabari B et al (2005) ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 280:36541–36544PubMedCrossRefGoogle Scholar
  2. Bajada S, Harrison PE, Ashton BA et al (2007) Successful treatment of refractory tibial nonunion using calcium sulphate and bone marrow stromal cell implantation. J Bone Joint Surg Br 89:1382–1386PubMedCrossRefGoogle Scholar
  3. Barbash IM, Chouraqui P, Baron J et al (2003) Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 108:863–868PubMedCrossRefGoogle Scholar
  4. Barrilleaux BL, Phinney DG, Fischer-Valuck BW et al (2009) Small-molecule antagonist of macrophage migration inhibitory factor enhances migratory response of mesenchymal stem cells to bronchial epithelial cells. Tissue Eng Part A 15:2335–2346PubMedCrossRefGoogle Scholar
  5. Barrilleaux BL, Phinney DG, Prockop DJ et al (2006) Ex vivo engineering of living tissue with adult stem cells. Tissue Eng 12:3007–3019PubMedCrossRefGoogle Scholar
  6. Bloom BR, Bennett B (1966) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153:80–82PubMedCrossRefGoogle Scholar
  7. Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791–800PubMedCrossRefGoogle Scholar
  8. Cheng KF, Al-Abed Y (2006) Critical modifications of the ISO-1 scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg Med Chem Lett 16:3376–3379PubMedCrossRefGoogle Scholar
  9. Colter DC, Sekiya I, Prockop, DJ (2001) Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci USA 98:7841–7845PubMedCrossRefGoogle Scholar
  10. Cvetkovic I, Al-Abed Y, Miljkovic D et al (2005) Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 146:2942–2951PubMedCrossRefGoogle Scholar
  11. David JR (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56:72–77PubMedCrossRefGoogle Scholar
  12. Denker AE, Haas AR, Nicoll SB et al (1999) Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: I. Stimulation by bone morphogenetic protein-2 in high-density micromass cultures. Differentiation 64:67–76PubMedCrossRefGoogle Scholar
  13. Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317PubMedCrossRefGoogle Scholar
  14. Emonts M, Sweep FC, Grebenchtchikov N et al (2007) Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis 44:1321–1328PubMedCrossRefGoogle Scholar
  15. Faure-André G, Vargas P, Yuseff MI et al (2008) Regulation of dendritic cell migration by CD74, the MHC class II-associated invariant chain. Science 322:1705–1710PubMedCrossRefGoogle Scholar
  16. Fox JM, Chamberlain G, Ashton BA et al (2007) Recent advances into the understanding of mesenchymal stem cell trafficking. Br J Haematol 137:491–502PubMedCrossRefGoogle Scholar
  17. Gray TE, Guzman K, Davis CW et al (1996) Mucociliary differentiation of serially passaged normal human tracheobronchial epithelial cells. Am J Respir Cell Mol Biol 14:104–112PubMedGoogle Scholar
  18. Gregory JL, Leech MT, David JR et al (2004) Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. Arthritis Rheum 50:3023–3034PubMedCrossRefGoogle Scholar
  19. Herrera MB, Bussolati B, Bruno S et al (2007) Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 72:430–441PubMedCrossRefGoogle Scholar
  20. Ishii M, Koike C, Igarashi A et al (2005) Molecular markers distinguish bone marrow mesenchymal stem cells from fibroblasts. Biochem Biophys Res Commun 332:297–303PubMedCrossRefGoogle Scholar
  21. Jaganathan BG, Ruester B, Dressel L et al (2007) Rho inhibition induces migration of mesenchymal stromal cells. Stem Cells 25:1966–1974PubMedCrossRefGoogle Scholar
  22. Karp PH, Moninger TO, Weber SP et al (2002) An in vitro model of differentiated human airway epithelia. Methods for establishing primary cultures. Methods Mol Biol 188:115–137PubMedGoogle Scholar
  23. Leng L, Metz CN, Fang Y et al (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197:1467–1476PubMedCrossRefGoogle Scholar
  24. Lubetsky JB, Dios A, Han, J et al (2002) The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 277:24976–24982PubMedCrossRefGoogle Scholar
  25. Merchant S, Nadaraj S, Chowdhury D et al (2008) Macrophage migration inhibitory factor in pediatric patients undergoing surgery for congenital heart repair. Mol Med 14:124–130PubMedCrossRefGoogle Scholar
  26. Nicoletti F, Créange A, Orlikowski D et al (2005) Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barré syndrome and experimental allergic neuritis. J Neuroimmunol 168:168–174PubMedCrossRefGoogle Scholar
  27. Ortiz LA, Gambelli F, McBride C et al (2003) Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 100:8407–8411PubMedCrossRefGoogle Scholar
  28. Ozaki Y, Nishimura M, Sekiya K et al (2007) Comprehensive analysis of chemotactic factors for bone marrow mesenchymal stem cells. Stem Cells Dev 16:119–129PubMedCrossRefGoogle Scholar
  29. Phinney DG (2007) Biochemical heterogeneity of mesenchymal stem cell populations. Cell Cycle 6:2884–2889PubMedCrossRefGoogle Scholar
  30. Sakuragi T, Lin X, Metz CN et al (2007) Lung-derived macrophage migration inhibitory factor in sepsis induces cardio-circulatory depression. Surg Infect (Larchmt) 8:29–40CrossRefGoogle Scholar
  31. Santos LL, Dacumos A, Yamana J et al (2008) Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation. Clin Exp Immunol 152:372–380PubMedCrossRefGoogle Scholar
  32. Sekiya I, Larson BL, Smith JR et al (2002) Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 20:530–541PubMedCrossRefGoogle Scholar
  33. Sekiya I, Larson BL, Vuoristo JT et al (2005) Comparison of effect of BMP-2, -4, and -6 on in vitro cartilage formation of human adult stem cells from bone marrow stroma. Cell Tissue Res 320:269–276PubMedCrossRefGoogle Scholar
  34. Tanino Y, Makita H, Miyamoto K et al (2002) Role of macrophage migration inhibitory factor in bleomycin-induced lung injury and fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 283:L156–L162PubMedGoogle Scholar
  35. Wakitani S, Mitsuoka T, Nakamura N et al (2004) Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports. Cell Transplant 13:595–600PubMedCrossRefGoogle Scholar
  36. Wang CC, Chen CH, Lin WW et al (2008) Direct intramyocardial injection of mesenchymal stem cell sheet fragments improves cardiac functions after infarction. Cardiovasc Res 77:515–524PubMedCrossRefGoogle Scholar
  37. Wilson JM, Coletta PL, Cuthbert RJ et al (2005) Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 129:1485–1503PubMedCrossRefGoogle Scholar
  38. Zhang J, Gong JF, Zhang W et al (2008) Effects of transplanted bone marrow mesenchymal stem cells on the irradiated intestine of mice. J Biomed Sci 15:585–594PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Kim C. O’Connor
    • 1
  • Bonnie L. Barrilleaux
    • 1
  • Donald G. Phinney
    • 2
  • Benjamin W. Fischer-Valuck
    • 1
  • Katie C. Russell
    • 1
  • Darwin J. Prockop
    • 3
  1. 1.Department of Chemical and Biomolecular Engineering and Tulane Center for Gene TherapyTulane UniversityNew OrleansUSA
  2. 2.Department of Molecular TherapeuticsThe Scripps Research InstituteJupiterUSA
  3. 3.Department of Molecular and Cellular Medicine, College of MedicineTexas A&M Health Science CenterTempleUSA

Personalised recommendations